CLINICAL TRIAL: NCT00856765
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'Yes',
                                     'authority' => [
                                                    'Netherlands: Ministry of Health, Welfare and Sport',
                                                    'Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)'
                                                  ]
                                   },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'March 2013',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => {
                                      'time_frame' => '6 months',
                                      'measure' => 'Angiographic in-segment late lumen loss (expressed in millimeters)  as determined by quantitative coronary analysis (QCA)',
                                      'safety_issue' => 'No'
                                    },
                 'intervention' => [
                                   {
                                     'other_name' => 'Dior (EuroCor)',
                                     'intervention_type' => 'Device',
                                     'arm_group_label' => '1',
                                     'description' => 'Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel',
                                     'intervention_name' => 'Drug eluting balloon'
                                   },
                                   {
                                     'other_name' => 'Magic (EuroCor)',
                                     'intervention_type' => 'Device',
                                     'arm_group_label' => [
                                                          '1',
                                                          '3'
                                                        ],
                                     'description' => 'Bare metal stent',
                                     'intervention_name' => 'Bare metal stent'
                                   },
                                   {
                                     'other_name' => "Taxus Libert\x{e9} (Boston scientific)",
                                     'intervention_type' => 'Device',
                                     'arm_group_label' => '2',
                                     'description' => 'Paclitaxel eluting stent',
                                     'intervention_name' => 'Drug eluting stent'
                                   }
                                 ],
                 'has_expanded_access' => 'No',
                 'arm_group' => [
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => 'Drug eluting balloon followed immediately by implantation of bare metal stent',
                                  'arm_group_label' => '1'
                                },
                                {
                                  'arm_group_type' => 'Active Comparator',
                                  'description' => 'Drug eluting stent',
                                  'arm_group_label' => '2'
                                },
                                {
                                  'arm_group_type' => 'Active Comparator',
                                  'description' => 'Bare metal stent',
                                  'arm_group_label' => '3'
                                }
                              ],
                 'number_of_arms' => '3',
                 'overall_official' => {
                                       'affiliation' => 'UMC Utrecht',
                                       'role' => 'Principal Investigator',
                                       'last_name' => 'Pieter Stella, MD'
                                     },
                 'brief_title' => 'Drug-eluting Balloon in Acute Myocardial Infarction',
                 'study_design' => 'Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment',
                 'location' => [
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Giuseppe M Sangiorgi, MD'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'last_name' => 'Giuseppe M Sangiorgi, MD'
                                            },
                                 'facility' => {
                                               'name' => 'University of Modena, Department of Cardiology',
                                               'address' => {
                                                            'country' => 'Italy',
                                                            'city' => 'Modena'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => [
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => 'Pierfrancesco Agostoni, MD, PhD'
                                                   },
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => 'Eric Van Belle, MD, PhD'
                                                   },
                                                   {
                                                     'role' => 'Principal Investigator',
                                                     'last_name' => 'Pieter Stella, MD'
                                                   }
                                                 ],
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'p.stella@umcutrecht.nl',
                                              'phone' => '+31887556167',
                                              'last_name' => 'Pieter Stella, MD'
                                            },
                                 'facility' => {
                                               'name' => 'UMC Utrecht',
                                               'address' => {
                                                            'country' => 'Netherlands',
                                                            'zip' => '3584 cx',
                                                            'city' => 'Utrecht'
                                                          }
                                             }
                               }
                             ],
                 'acronym' => 'DEB-AMI',
                 'id_info' => {
                              'nct_id' => 'NCT00856765',
                              'org_study_id' => 'METC 08-255'
                            },
                 'firstreceived_date' => 'March 5, 2009',
                 'overall_contact' => {
                                      'email' => 'p.stella@umcutrecht.nl',
                                      'phone' => '+31887556167',
                                      'last_name' => 'Pieter Stella, MD'
                                    },
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'March 2009',
                 'source' => 'UMC Utrecht',
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'UMC Utrecht'
                                               }
                             },
                 'completion_date' => {
                                      'content' => 'March 2018',
                                      'type' => 'Anticipated'
                                    },
                 'official_title' => 'Randomized Comparison of Drug Eluting Balloon/Bare Metal Stent Versus Drug Eluting Stent Versus Bare Metal Stent for the Treatment of Patients With Acute ST-elevation Myocardial Infarction',
                 'enrollment' => {
                                 'content' => '150',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => [
                                                      'Atherosclerosis',
                                                      'Coronary Artery Disease',
                                                      'Myocardial Ischemia',
                                                      'Coronary Disease',
                                                      'Infarction',
                                                      'Myocardial Infarction',
                                                      'Thrombosis'
                                                    ]
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      The investigators hypothesize that patients with Acute ST Elevation Myocardial Infarction
      may benefit from primary angioplasty with use of a drug eluting balloon/bare metal stent
      combination without impairing the process of normal vascular healing and endothelial
      function.

      The goals of this study are:

        1. To compare 6-month angiographic outcome after primary angioplasty using drug eluting
           balloon/bare metal stent combination versus drug eluting stent versus bare metal stent.

        2. To compare stent apposition and stent endothelialization after primary angioplasty
           using drug eluting balloon/bare metal stent versus drug eluting stent versus bare metal
           stent.

        3. To compare coronary endothelial function after primary angioplasty using drug eluting
           balloon/bare metal stent versus drug eluting stent versus bare metal stent.
    '
                                  },
                 'location_countries' => {
                                         'country' => [
                                                      'Italy',
                                                      'Netherlands'
                                                    ]
                                       },
                 'secondary_outcome' => [
                                        {
                                          'time_frame' => '6 months',
                                          'measure' => 'Binary restenosis using QCA',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => '6 months',
                                          'measure' => 'stent malapposition and re-endothelialization assessed by Optical Coherence Tomography (OCY)',
                                          'safety_issue' => 'Yes'
                                        },
                                        {
                                          'time_frame' => '6 months',
                                          'measure' => 'coronary endothelial dysfunction after acetylcholine infusion',
                                          'safety_issue' => 'Yes'
                                        },
                                        {
                                          'time_frame' => '5 years',
                                          'measure' => 'Clinical outcomes (death, myocardial infarction, repeated revascularization procedures)',
                                          'safety_issue' => 'Yes'
                                        }
                                      ],
                 'responsible_party' => {
                                        'name_title' => 'Dr. Pieter Stella',
                                        'organization' => 'UMC Utrecht'
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '18 Years',
                                  'criteria' => {
                                                'textblock' => '
        Inclusion Criteria:

          -  STEMI within 12 hours of onset of complaints

          -  Candidate for primary PCI with stent-implantation

          -  Successful thrombus aspiration defined by no angiographic signs of thrombus a the
             site of plaque rupture and TIMI flow more or equal 1

        Exclusion Criteria:

          -  Unable to give written informed consent

          -  Diabetes and Type C- coronary lesion

          -  Previous PCI or CABG of infarct related vessel

          -  Left main stenosis more than 50%.

          -  Triple vessel disease with stenosis more than 50% in 3 epicardial coronary arteries

          -  Target vessel reference diameter less than 2.5 and more than 4.0 mm

          -  Target lesion length more than 25 mm

          -  Intolerance for aspirin or clopidogrel

          -  Life expectancy less than 12 months

          -  Women with child bearing potential
      '
                                              },
                                  'maximum_age' => '80 Years',
                                  'gender' => 'Both'
                                },
                 'phase' => 'Phase 2/Phase 3',
                 'lastchanged_date' => 'June 29, 2010',
                 'start_date' => 'March 2009',
                 'is_fda_regulated' => 'No',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 07, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT00856765',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'condition' => [
                                'Coronary Artery Disease',
                                'Atherosclerosis',
                                'Thrombosis',
                                'Acute Myocardial Infarction'
                              ]
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ### 

 ##### 
time_frame	6 months
measure	Angiographic in-segment late lumen loss (expressed in millimeters)  as determined by quantitative coronary analysis (QCA)
safety_issue	No
other_name	Dior (EuroCor)
intervention_type	Device
arm_group_label	1
description	Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
intervention_name	Drug eluting balloon
other_name	Magic (EuroCor)
intervention_type	Device
arm_group_label	1
arm_group_label	3

description	Bare metal stent
intervention_name	Bare metal stent
other_name	Taxus Liberté (Boston scientific)
intervention_type	Device
arm_group_label	2
description	Paclitaxel eluting stent
intervention_name	Drug eluting stent
Study Title: Randomized Comparison of Drug Eluting Balloon/Bare Metal Stent Versus Drug Eluting Stent Versus Bare Metal Stent for the Treatment of Patients With Acute ST-elevation Myocardial Infarction
Keyword	NOT FOUND
lead_sponsor	HASH(0x9de0358)

MeSH	NOT FOUND
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01322009
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'Yes',
                                     'authority' => 'United States: Institutional Review Board'
                                   },
                 'detailed_description' => {
                                           'textblock' => '
      Specific Aim: Define the capacity of the combination of probenecid and NAC to safely and
      synergistically preserve levels of GSH and reduce oxidative stress in children with severe
      TBI. We will enroll 20 children age 2 to less than 18 years old (less than 216 months) after
      severe TBI in a randomized, controlled study of administration of the combinational therapy
      and test if the administration of these drugs is safe and if antioxidant reserve can be
      preserved within the serum and CSF.

      Probenecid (at the same dose that is used as an adjunct to antibiotic therapy) and NAC (at
      the same dose that is used for acetaminophen-induced liver disease), or vehicles will be
      given for 3 days. The primary outcomes of the study will be the safety of drug
      administration and the CSF and serum levels anti-oxidant reserve (AOR), with the presumption
      that maintaining anti-oxidant levels within the brain may prove neuroprotective. Other
      secondary outcomes (CSF and serum probenecid, NAC, GSH and phenytoin concentrations) will
      also be tested. Adverse events occuring during treatment with these drugs after TBI will be
      monitored by a local Data Safety Monitoring Board.
    '
                                         },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'March 2014',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => {
                                      'time_frame' => '14 days after drug administration',
                                      'measure' => 'Adverse Events',
                                      'description' => 'A number of a prior defined adverse events have been defined. The number of adverse events in the treatment arms will be calculated and compared.',
                                      'safety_issue' => 'Yes'
                                    },
                 'intervention' => [
                                   {
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'Drug',
                                     'description' => 'After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days or to receive placebos.',
                                     'intervention_name' => 'Probenecid and N-acetyl cysteine'
                                   },
                                   {
                                     'other_name' => 'Ora Plus',
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'Placebo',
                                     'description' => 'After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days. Placebo contents include equal volumes and dosing regimens of lactose powder (for opacity) suspended in Ora-Plus and normal saline.',
                                     'intervention_name' => 'Placebo'
                                   }
                                 ],
                 'intervention_browse' => {
                                          'mesh_term' => [
                                                         'Acetylcysteine',
                                                         'N-monoacetylcystine',
                                                         'Probenecid'
                                                       ]
                                        },
                 'has_expanded_access' => 'No',
                 'number_of_arms' => '2',
                 'arm_group' => [
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => 'Probenecid and N-acetyl cysteine will be administered at standard doses for the first 4 days after TBI.',
                                  'arm_group_label' => 'Drug'
                                },
                                {
                                  'arm_group_type' => 'Placebo Comparator',
                                  'description' => 'Placebos will be prepared for the two experimental drugs and administered at identical time periods.',
                                  'arm_group_label' => 'Placebo'
                                }
                              ],
                 'overall_official' => [
                                       {
                                         'affiliation' => 'University of Pittsburgh',
                                         'role' => 'Principal Investigator',
                                         'last_name' => 'Michael J Bell, MD'
                                       },
                                       {
                                         'affiliation' => 'University of Pittsburgh',
                                         'role' => 'Study Director',
                                         'last_name' => 'Robert SB Clark, MD'
                                       }
                                     ],
                 'brief_title' => 'Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury',
                 'study_design' => 'Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment',
                 'location' => {
                               'investigator' => [
                                                 {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Michael J Bell, MD'
                                                 },
                                                 {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Robert SB Clark, MD'
                                                 }
                                               ],
                               'status' => 'Recruiting',
                               'contact' => {
                                            'email' => 'bellmj4@upmc.edu',
                                            'phone' => '412-692-5164',
                                            'last_name' => 'Michael J Bell, MD'
                                          },
                               'facility' => {
                                             'name' => 'Children\'s Hospital of Pittsburgh of UPMC',
                                             'address' => {
                                                          'country' => 'United States',
                                                          'zip' => '15213',
                                                          'city' => 'Pittsburgh',
                                                          'state' => 'Pennsylvania'
                                                        }
                                           }
                             },
                 'acronym' => 'Pro-NAC',
                 'id_info' => {
                              'secondary_id' => '1R01NS069247-01',
                              'nct_id' => 'NCT01322009',
                              'org_study_id' => 'NS069247'
                            },
                 'overall_contact' => {
                                      'email' => 'bellmj4@upmc.edu',
                                      'phone' => '412-692-5164',
                                      'last_name' => 'Michael J Bell, MD'
                                    },
                 'firstreceived_date' => 'March 22, 2011',
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'March 2011',
                 'keyword' => [
                              'Children',
                              'Brain injury',
                              'Trauma'
                            ],
                 'source' => 'University of Pittsburgh',
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'University of Pittsburgh'
                                               },
                               'collaborator' => [
                                                 {
                                                   'agency_class' => 'NIH',
                                                   'agency' => 'National Institutes of Health (NIH)'
                                                 },
                                                 {
                                                   'agency_class' => 'NIH',
                                                   'agency' => 'National Institute of Neurological Disorders and Stroke (NINDS)'
                                                 }
                                               ]
                             },
                 'completion_date' => {
                                      'content' => 'March 2014',
                                      'type' => 'Anticipated'
                                    },
                 'official_title' => 'Overcoming Membrane Transporters to Improve CNS Drug Delivery',
                 'enrollment' => {
                                 'content' => '20',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => 'Brain Injuries'
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      The overall purpose of this research study is to investigate the safety of pharmacological
      therapies that may potentially improve pediatric outcomes after traumatic brain injury.
      Traumatic brain injuries are the leading cause of death and disability among children and
      young adults.

      Hypothesis: Combinational therapy with a membrane transporter and antioxidant are safe after
      TBI and can overcome barriers to the brain and synergistically improve bioavailability and
      efficacy the antioxidant content of the body and CNS after TBI.
    '
                                  },
                 'location_countries' => {
                                         'country' => 'United States'
                                       },
                 'secondary_outcome' => {
                                        'time_frame' => 'Within 5 days of injury',
                                        'measure' => 'Antioxidant Reserve',
                                        'description' => 'Antioxidant reserves in CSF and serum will be calculated in both treatment arms and compared.',
                                        'safety_issue' => 'No'
                                      },
                 'responsible_party' => {
                                        'name_title' => 'Michael Bell/Associate Professor of Critical Care Medicine, Neurological Surgery and Pediatrics',
                                        'organization' => 'University of Pittsburgh'
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '2 Years',
                                  'criteria' => {
                                                'textblock' => '
        Inclusion Criteria:

          -  Children (age 2 - 18 y) with severe TBI (GCS < or = 8) with an externalized
             ventricular drain placed for measurement of intracranial pressure

        Exclusion Criteria:

          1. Brain dead on admission to ICU

          2. Pregnancy

          3. Contraindications to enteral medications

          4. Contraindications to probenecid:

               -  status epilepticus

               -  blood dyscrasias

               -  under 2 years-of-age

               -  coadministration of salicylates

               -  renal dysfunction or urate kidney stones

               -  hypersensitivity to probenecid

          5. Contraindications to N-acetylcysteine: hypersensitivity to N-acetylcysteine

          6. Family unwilling to consent
      '
                                              },
                                  'maximum_age' => '18 Years',
                                  'gender' => 'Both'
                                },
                 'lastchanged_date' => 'March 23, 2011',
                 'phase' => 'Phase 1/Phase 2',
                 'start_date' => 'March 2011',
                 'is_fda_regulated' => 'No',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 07, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT01322009',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'condition' => 'Pediatric Traumatic Brain Injury'
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ### 

 ##### 
time_frame	14 days after drug administration
measure	Adverse Events
description	A number of a prior defined adverse events have been defined. The number of adverse events in the treatment arms will be calculated and compared.
safety_issue	Yes
intervention_type	Drug
arm_group_label	Drug
description	After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days or to receive placebos.
intervention_name	Probenecid and N-acetyl cysteine
other_name	Ora Plus
intervention_type	Drug
arm_group_label	Placebo
description	After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days. Placebo contents include equal volumes and dosing regimens of lactose powder (for opacity) suspended in Ora-Plus and normal saline.
intervention_name	Placebo
Study Title: Overcoming Membrane Transporters to Improve CNS Drug Delivery
